talazoparib + rifampin

This entry refers to the combination of **talazoparib**, a potent poly(ADP-ribose) polymerase (PARP) inhibitor used primarily as an antineoplastic agent, and **rifampin**, a well-known antibiotic and a strong inducer of cytochrome P450 (CYP) enzymes and P-glycoprotein (P-gp) transporter. Talazoparib inhibits PARP1 and PARP2, promoting synthetic lethality in tumor cells with homologous recombination repair deficiency, such as BRCA-mutated cancers. Rifampin is primarily used for the treatment and prophylaxis of tuberculosis and as an inducer in drug-drug interaction studies. When used together, rifampin as a P-gp inducer can alter the pharmacokinetics of talazoparib, specifically increasing the maximum plasma concentration (Cmax) of talazoparib by about 37%, while not significantly impacting its area under the curve (AUC)[1][2][3][4][5]. This combination has been studied for drug-drug interaction, rather than for a therapeutic indication.

Brand names

TalzennaRifadin

Other names

talazoparibBMN 673BMN673BMN-673rifampinrifampicin